Skip to main content
. 2021 Feb 2;141(3):383–397. doi: 10.1007/s00401-021-02270-x

Table 3.

Brain and peripheral tissue samples bioassay results in Methionine 129 Human PrP–expressing mice (tgMet) for sCJD patients

sCJD 1 (96–1999) sCJD 2 (21/2006) sCJD 3 (02/83) sCJD 4 (03/20) sCJD 5 (31/2009) Negative control
Tissue n/n0 Suriv. time Inf. tit estimates n/n0 Suriv time Inf. tit estimates n/n0 Suriv time Inf. tit estimates n/n0 Suriv time Inf. tit estimates n/n0 Suriv time Inf. tit estimates n/n0 Suriv time
Frontal cortex 6/6 215 ± 8 107.2 (106.7, 107.7) 5/5 201 ± 6 107.8 (107.2, 108.3) 5/5 236 ± 9 106.4 (105.9, 106.9) 6/6 225 ± 14 105.8 (105.4, 106.3) 6/6 219 ± 18 106.1 (105.6,106.6) 0/6  > 750
Cervical Lymph node 0/6  > 750 6/6 335 ± 47 103 (102.7, 103.4) 0/6  > 750 0/6  > 750 2/6 294,326 102.9 (102.4,103.4) 0/6  > 750
Tonsil 0/6  > 750 6/6 298 ± 21 104.2 (103.8, 103.7) 0/6  > 750 1/6 380 102 (101.2, 102.6) 1/6 486 100.1 (10–0.9,101.2) 0/6  > 750
Spleen NA 1/5 318 ± 21 102.5 (102.1, 102.9) 0/6  > 750 0/6  > 750 0/6  > 750 0/6  > 750
Thymus NA NA NA NA 4/6 347 ± 19 102.2 (101.7,102.5) 0/6  > 750
Lung 5/5 321 ± 21 103.3 (102.9, 103.8) 0/6  > 750 3/6 370 ± 98 100.5 (10–0.2, 101.2) 0/6  > 750 0/6  > 750 0/6  > 750
Heart 5/6 329 ± 43 102.9 (102.6, 103.3) 5/6 381 ± 58 102.2 (101.9, 102.5) 0/6  > 750 0/6  > 750 1/6 538 10–3.4 (10–4.5,10–2.2) 0/6  > 750
Liver 0/6  > 750 0/6  > 600 0/6  > 750 0/6  > 750 0/6  > 750 0/6  > 750
Kidney 1/6 403 101.6 (100.5, 102.3) 2/6 302,393 102.7 (102.2, 103.3) 0/6  > 750 1/6 381 101.9 (101.1, 102.4) 0/6  > 750 0/6  > 750
Salivary gland 5/6 387 ± 61 102.1 (101.7, 102.5) 4/6 367 ± 60 102.1 (101.6, 102.6) 0/6  > 750 0/6  > 750 2/6 730,732 10–0.52 (10–1.8,101.1) 0/6  > 750
Pancreas 0/6  > 750 2/6 291,331 102.8 (102.1, 102.6) 0/6  > 750 5/6 348 ± 63 102.7 (102.4, 103) 1/6 477 100.1 (10–1.2,100.4) 0/6  > 750
Thyroid NA 0/6  > 750 0/6  > 750 1/6 414 101.4 (100.2, 102.1) 0/6  > 750 0/6  > 750
Adrenal gland 3/6 526 ± 63 10–0.6 (10–1.1, 100.2) 6/6 301 ± 9 104 (103.6, 104.5) 5/6 333 ± 32 102.8 (102.5, 103.2) 2/6 345,348 102.2 (101.8, 102.6) 3/6 419 ± 89 100.1 (10–0.9,101.2) 0/6  > 750
Bone marrow 6/6 264 ± 11 104.4 (103.9,104.9) 6/6 359 ± 38 101.6 (101.3, 101.9) 3/6 409 ± 18 100.2 (100, 100.9) 6/6 311 ± 19 102.7 (102.2, 103.1) 6/6 316 ± 18 102.5 (102.1,102.9) 0/6  > 750
Skeletal muscle 1/6 485 10–1.4 (10–2.5, 10–0.2) 5/5 304 ± 32 103.9 (103.4, 104.4) 3/6 484 ± 81 10–0.2 (10–0.8, 100.5) 0/6  > 750 0/6  > 750 0/6  > 750
Testis NA
Ovary 0/6  > 750 NA NA 0/6  > 750 0/6  > 750

Tg Met mice were inoculated with homogenates (10% weight / volume) of tissues that had been collected post mortem from symptomatic sCJD patients (sCJD-1 to sCJD-5). All the sCJD patients were homozygous for methionine at codon 129 of the PRNP gene and displayed a type 1 abnormal PrP profile in their brain. Tissues from a methionine at codon 129 individual that was not affected with CJD (negative control) were also inoculated in tg Met. Mice were killed when they showed clinical signs of prion infection or after 750-days post-inoculation. Mice were considered prion infected when abnormal PrP deposition was detected in brain by Western Blot (PrPres -antibody Sha31 epitope YEDRYYRE). Survival times are presented as mean ± SD except when less than three animals were positive. In that case individual survival time of positive animals are reported. Infectious prion titres were estimated by using the method of Arnold et al. [4]. The method uses the probability of survival (attack rate at each dilution) and the individual mouse incubation time at each dilution to estimate infectious load. Infectious titres are given as estimated values

LD50 50% lethal dose with lower and higher boundaries of the CI95%, Suriv. survival, Inf infectious, n number of abnormal, PrP positive mice by western blot, n0 number of inoculated mice; NA not available, PrP prion protein, sCJD sporadic Creutzfeldt–Jakob disease; tit titre